Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;9(3):e1001194.
doi: 10.1371/journal.pmed.1001194. Epub 2012 Mar 20.

CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE

Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord; Jim Young, Mina Psichogiou, Laurence Meyer, Sylvie Ayayi, Sophie Grabar, Francois Raffi, Peter Reiss, Brian Gazzard, Mike Sharland, Félix Gutierrez, Niels Obel, Ole Kirk, José M Miro, Hansjakob Furrer, Antonella Castagna, Stéphane De Wit, Josefa Muñoz, Jesper Kjaer, Jesper Grarup, Geneviève Chêne, Heiner Bucher
Collaborators

CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE

Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord et al. PLoS Med. 2012.

Abstract

Background: Most adults infected with HIV achieve viral suppression within a year of starting combination antiretroviral therapy (cART). It is important to understand the risk of AIDS events or death for patients with a suppressed viral load.

Methods and findings: Using data from the Collaboration of Observational HIV Epidemiological Research Europe (2010 merger), we assessed the risk of a new AIDS-defining event or death in successfully treated patients. We accumulated episodes of viral suppression for each patient while on cART, each episode beginning with the second of two consecutive plasma viral load measurements <50 copies/µl and ending with either a measurement >500 copies/µl, the first of two consecutive measurements between 50-500 copies/µl, cART interruption or administrative censoring. We used stratified multivariate Cox models to estimate the association between time updated CD4 cell count and a new AIDS event or death or death alone. 75,336 patients contributed 104,265 suppression episodes and were suppressed while on cART for a median 2.7 years. The mortality rate was 4.8 per 1,000 years of viral suppression. A higher CD4 cell count was always associated with a reduced risk of a new AIDS event or death; with a hazard ratio per 100 cells/µl (95% CI) of: 0.35 (0.30-0.40) for counts <200 cells/µl, 0.81 (0.71-0.92) for counts 200 to <350 cells/µl, 0.74 (0.66-0.83) for counts 350 to <500 cells/µl, and 0.96 (0.92-0.99) for counts ≥500 cells/µl. A higher CD4 cell count became even more beneficial over time for patients with CD4 cell counts <200 cells/µl.

Conclusions: Despite the low mortality rate, the risk of a new AIDS event or death follows a CD4 cell count gradient in patients with viral suppression. A higher CD4 cell count was associated with the greatest benefit for patients with a CD4 cell count <200 cells/µl but still some slight benefit for those with a CD4 cell count ≥500 cells/µl.

PubMed Disclaimer

Conflict of interest statement

HCB has received travel grants, honoraria and unrestricted research grants from various pharmaceutical companies, including GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS), Gilead, Janssen, Roche, Abbott, Tibotec, Boehringer-Ingelheim, and ViiV Healthcare; HF has received payment for participation on advisory boards, unrestricted educational grants or travel grants from Abbott, BMS, ViiV Healthcare, Roche, Gilead, MSD, Boehringer-Ingelheim, and Tibotec-Janssen, and unrestricted research support from Gilead, MSD, and Roche; FG has received honoraria for participation on advisory boards, unrestricted educational grants or travel grants from Abbott, BMS, ViiV Healthcare, Gilead, MSD, Boehringer-Ingelheim, and Tibotec-Janssen; GC has received honoraria from Roche; PR has served as a scientific advisor to Boehringer Ingelheim Pharmaceuticals, BMS, Gilead Sciences, GSK, ViiV Healthcare, Merck, Theratechnologies, Tibotec Therapeutics, Tobira Therapeutics, and Ferrer, has served on data and safety monitoring boards and endpoint adjudication committees for Tibotec Therapeutics, has received honoraria for speaking engagements at scientific conferences from Boehringer Ingelheim Pharmaceuticals, BMS, Gilead Sciences, GSK, and Theratechnologies, has received research support from Gilead Sciences, ViiV Healthcare, Tibotec, BMS, Merck, Abbott, and Boehringer Ingelheim Pharmaceuticals; JMM has received payment for participation on advisory boards, consultancy or lecturing from Abbott, Boehringer-Ingelheim, BMS, Cubist, GSK, Gilead Sciences, Janssen-Cilag, Merck, Novartis, Pfizer, Roche, Schering-Plough, Theravance, and ViiV. JY, MP, LM, SA, SG, FR, BG, MS, NO, OK, AC, SDW, JM, JK, CC, and JG all declare no conflicts of interest.

Figures

Figure 1
Figure 1. Probability plots of AIDS event-free survival over time.
These plots apply to hypothetical patients whose CD4 cell count remains within the same CD4 stratum while on cART with a suppressed viral load. Plot (A) shows a Kaplan Meier plot of the probability of AIDS event-free survival over time. Plot (B) shows a plot of log(−log [probability of AIDS event-free survival]) against log(time). The roughly parallel lines of plot (B) suggest that a proportional hazards model is appropriate for these data. Both plots use a method appropriate for a time-dependent CD4 cell count (see [16]).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006;368:451–458. - PubMed
    1. Vo TT, Ledergerber B, Keiser O, Hirschel B, Furrer H, et al. Durability and outcome of initial antiretroviral treatments received during 2000–2005 by patients in the Swiss HIV Cohort Study. J Infect Dis. 2008;197:1685–1694. - PubMed
    1. Egger M, May M, Chene G, Phillips AN, Ledergerber B, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129. - PubMed
    1. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679–686. - PubMed
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2011. Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 17 October 2011.

Publication types

Substances